Significant Progress for Pluristem: PLX Cells Were Selected for European Medicines Agency's Adaptive Pathways Pilot Project Print E-mail
Monday, 18 May 2015 14:33
HAIFA, Israel--Pluristem Therapeutics Inc. (PSTI), a leading developer of placenta-based cell therapy products, today announced a significant advancement to its clinical development plan: the PLX cell program in critical limb ischemia has been selected for the European Medicines Agency's Adaptive Pathways pilot project.
Read more...
 
Pluristem’s PLX Cells One Step Closer to Entering Japan’s Accelerated Pathway for Regenerative Medicine Print E-mail
Wednesday, 13 May 2015 07:38
HAIFA, ISRAEL, May 13, 2015 -- Pluristem Therapeutics Inc. (NasdaqCM: PSTI, TASE: PLTR), a leading developer of placenta-based cell therapy products, today announced that Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) agreed with the proposed quality and large-scale manufacturing methods for PLX-PAD cells for use in clinical trials.
Read more...
 
PlasmaTech Biopharmaceuticals Announces Appointment of Todd Wider, MD to Board of Director Print E-mail
Tuesday, 12 May 2015 18:18
PlasmaTech Biopharmaceuticals, Inc. ("PlasmaTech" or the "Company") (NASDAQ: PTBI), a biopharmaceutical company focused on advancing cell therapy and gene therapy for rare diseases, announced today that Todd Wider, MD has been elected to the Company's Board of Directors.
Read more...
 
Lubrizol to Showcase Expanded Global Solutions at IATI Biomed 2015 Print E-mail
Tuesday, 12 May 2015 00:43
CLEVELAND, May 12, 2015 - The Lubrizol Corporation announces that its LifeSciences business (Booth 66) will showcase its total solutions capabilities, including those from the acquisition of Vesta and recent alliance with Particle Sciences at IATI Biomed 2015 in Tel Aviv, Israel.
Read more...
 
Understanding Radiation Proctitis: New Approach Addresses the Needs of Ovarian, Colon and Prostate Cancer Patients Print E-mail
Thursday, 07 May 2015 17:54
Newswise — Radiation Proctitis (“RP”) is a term used to describe the inflammation and damage to the lower portion of the colon following exposure to x-rays or ionizing radiation as part of radiation therapy.
Read more...
 
PlasmaTech Biopharmaceuticals' Announces $10 Million Private Placement Print E-mail
Wednesday, 06 May 2015 19:15
DALLAS, TX and NEW YORK, NY--PlasmaTech Biopharmaceuticals, Inc. ("PlasmaTech" or the "Company"), (NASDAQ: PTBI), announced today that it has entered into a definitive agreement with one institutional investor in a private placement of approximately $10 million of common stock at a price of $8.00 per share, or 1,250,000 shares.
Read more...
 
Provectus Biopharmaceuticals’s Novel Synthesis Patent Application Allowed by European Patent Office, Patent Issued by Japan Print E-mail
Wednesday, 06 May 2015 00:23
KNOXVILLE, Tenn--Provectus Biopharmaceuticals, Inc. (NYSE MKT:PVCT, http://www.pvct.com), a clinical-stage oncology and dermatology biopharmaceutical company (“Provectus” or the “Company”), announced that it has received notification of allowance from the European Patent Office for its patent application protecting the synthetic process used to produce the small molecule Rose Bengal, the active pharmaceutical ingredient (API) in PV-10, the ’Company’s lead oncology drug candidate.
Read more...
 
PROVECTUS BIOPHARMACEUTICALS’S NOVEL SYNTHESIS PATENT APPLICATION ALLOWED BY EUROPEAN PATENT OFFICE, PATENT ISSUED BY JAPAN Print E-mail
Tuesday, 05 May 2015 12:54
KNOXVILLE, TN--Provectus Biopharmaceuticals, Inc. (NYSE MKT: PVCT, http://www.pvct.com), a clinical-stage oncology and dermatology biopharmaceutical company (“Provectus” or the “Company”), announced that it has received notification of allowance from the European Patent Office for its patent application protecting the synthetic process used to produce the small molecule Rose Bengal, the active pharmaceutical ingredient (API) in PV-10, the ’Company’s lead oncology drug candidate.
Read more...
 
PlasmaTech Biopharmaceuticals Bolsters Scientific Advisory Board With Alpha-1 Expert Charlie Strange, M.D. Print E-mail
Tuesday, 14 April 2015 10:21
DALLAS/NEW YORK CITY--PlasmaTech Biopharmaceuticals, Inc. PTBI, -2.09% a biopharmaceutical company advancing protein biologic therapies and oncology supportive care products, announced today it had appointed Charlie Strange, M.D. to its Scientific Advisory Board (SAB).
Read more...
 
AAA Reports 29.8% Sales Growth in 2014 While Continuing to Show Significant Clinical Progress Across Both Therapeutic and Diagnostic Platforms Print E-mail
Thursday, 09 April 2015 19:28
NEW YORK/SAINT-GENIS-POUILLY, FRANCE--Advanced Accelerator Applications S.A. ("AAA" or "the Company"), an international specialist in Molecular Nuclear Medicine (MNM), today announced its Q4 and full year 2014 financial results.
Read more...
 
<< Start < Prev 1 2 3 4 5 6 7 8 9 10 Next > End >>

Page 4 of 12

Newsletter